Re: Tensha Therapeutics sold to Roche

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Tensha Therapeutics sold to Roche

in response to

Tensha Therapeutics sold to Roche

BKC

posted on Jan 12, 2016 03:00PM

Thanks for sharing BKC. Here's a link to the new story. And Tensha's lead molecule TEN-010 is a first generation BET inhibitor, whereas Zenith will be using next generation BET inhibitors.